...recently as VP corporate licenses, until 2014. Since then, Goupit has served on the boards of Inventiva S.A....

...Calliditas Therapeutics AB (SSE:CALTX; NASDAQ:CALT), which raised $87.9 million in June; and French NASH company Inventiva S.A....

...Deal with Multiple MOAs”). After elafibranor’s failure, the most advanced PPAR ɑ/ƍ agonist is lanifibranor from Inventiva S.A....
...data from the NATIVE trial demonstrated that the therapy outperformed Ocaliva on several measures (see “Inventiva...
...proliferation activated receptor alphaPPAR ƍ –  Peroxisome proliferation activated receptor delta Amanda Micklus Intercept Pharmaceuticals Inc. Genfit S.A. Novartis AG Pfizer Inc. Inventiva S.A. Farnesoid...

...on NASDAQ Friday. Also pricing offerings were CAR T company Poseida Therapeutics Inc. (NASDAQ:PSTX) and Inventiva S.A....
...“Rubius Turns to Cancer, Autoimmune” ). Two other listings The aftermarket performances of Poseida and Inventiva...
...shares bracketed their $16 offering price during Friday trading, finishing down $0.65 to $15.35, while Inventiva’s...

...series B round (see “Funding Clinical Programs, Manufacturing” ). Also due to trade Friday is Inventiva S.A....
...it would raise about $107.7 million. Inventiva’s pipeline includes treatments for non-alcoholic steatohepatitis and mucopolysaccharidoses. Inventiva’s...
...aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta Inc. Relay Therapeutics Inc. Inventiva S.A....

...their proposed offerings; each now plan to sell 10 million shares at $14-$16 on NASDAQ. Inventiva S.A....

...September 2019 series B round (see “Funding Clinical Programs, Manufacturing” ). French liver disease company Inventiva S.A....
...to treat NASH, driving a big gain for the company’s shares (see “Resuscitating Hopes” ; “Inventiva...

...from Intercept, which is under FDA review with a decision expected after June 26 (see “Inventiva...
...EMA. The outcomes were primary endpoints in the Intercept trial and secondary endpoints in the Inventiva...
...an 18-month readout for obeticholic acid. Stephen Hansen, Associate Editor lanifibranor (iva337) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Inventiva S.A. Intercept...

...mechanism for NASH after two PPAR agonists failed to show a benefit. Now, data for Inventiva’s...
...addition to meeting the primary endpoint of a Phase II trial, the pan-PPAR agonist from Inventiva S.A....
...endpoint of the Phase IIb NATIVE trial data was reduction steatosis activity fibrosis (SAF) score. Inventiva...

...for NASH and in Phase II studies for PBC and non-alcoholic fatty liver disease (NAFLD). Inventiva S.A....